RhoVac is developing RV001, a cancer immunotherapy designed to prevent or limit metastasis by activating T-cells against cells with metastatic potential. The therapy contains fragments of the protein RhoC, which is overexpressed in cells with metastatic potential across a range of cancers. The ongoing Phase IIb study in prostate cancer is fully funded and results are expected around mid-2021. RhoVac’s strategic aim is to secure a partner for the late-stage development of RV001. Anders Månsson, RhoVac’s chief executive officer, introduces the company and its lead asset, RV001 and provides an overview of R&D progress and expected newsflow.